Australia's most trusted
source of pharma news
Friday, 26 June 2026
Posted 26 June 2026 AM
Arrotex is on a roll, signing yet another agreement to bring an innovative medicine to Australia and New Zealand.
This deal is with Chinese pharma CStone Pharmaceuticals and licenses "an anti-PD-L1 monoclonal antibody treatment for lung and other types of cancer," likely referring to sugemalimab, which is marketed as Cejemly in Europe and the UK.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.